The Conversation (0)
Novartis announced today that it has acquired Selexys Pharmaceuticals, which specializes in developing treatments for select hematologic and inflammatory disorders.
Novartis (NYSE:NVS) announced today that it has acquired Selexys Pharmaceuticals, which specializes in developing treatments for select hematologic and inflammatory disorders.
According to the press release:
“Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease.”
Bruno Strigini, CEO of Novartis Oncology, said the following:
“Sickle cell disease affects millions of people around the world and there are limited therapies available for treatment of vaso-occlusive pain crises, a very common complication of the disease. With this acquisition, Novartis is able to leverage its leadership in hematology research to advance development of a potential new treatment option for patients living with this debilitating condition.”
Read the full press release here.